- Trials with a EudraCT protocol (28)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
28 result(s) found for: Renin inhibitors.
Displaying page 1 of 2.
EudraCT Number: 2008-007881-45 | Sponsor Protocol Number: SPP100ANL02T | Start Date*: 2009-03-12 | ||||||||||||||||
Sponsor Name:University Medical Center Groningen | ||||||||||||||||||
Full Title: A double-blind, placebo-controlled, randomized trial investigating the safety and efficacy of Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients w... | ||||||||||||||||||
Medical condition: Patients with chronic heart failure and reduced glomerular filtration rate. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000452-14 | Sponsor Protocol Number: FARM537JNE | Start Date*: 2007-08-29 | |||||||||||
Sponsor Name:CONSORZIO MARIO NEGRI SUD | |||||||||||||
Full Title: Long term impact of renin angiotensin system RAS inhibition on cardiorenal outcomes. A randomized controlled trial of cardio-renal effects of RAS inhibition in patients with cardio-renal risk. A... | |||||||||||||
Medical condition: Patients with one or more cardiovascular risk factors and microalbuminuria, diabetic or not diabetic. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-007149-30 | Sponsor Protocol Number: 4500 | Start Date*: 2009-01-14 | |||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge [...] | |||||||||||||
Full Title: Optimal Treatment of Drug Resistant Hypertension | |||||||||||||
Medical condition: Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001595-15 | Sponsor Protocol Number: 270389-010520 | Start Date*: 2020-06-23 | |||||||||||||||||||||
Sponsor Name:Henrik Birn | |||||||||||||||||||||||
Full Title: The Measures to Optimize RAAS-blockade in Patients with Hyperkalemia and Chronic Kidney Disease | |||||||||||||||||||||||
Medical condition: Chronic kidney disease with albuminuria | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-001929-24 | Sponsor Protocol Number: 1392-H-199 | Start Date*: 2011-09-19 |
Sponsor Name:Fundación para la Investigación Biomédica del Hospital 12 de Octubre | ||
Full Title: Randomised, open-label, crossover clinical trial to evaluate the antiproteinuric effect of three different types of diuretics (hydrochlorothiazide, amiloride and spironolactone) in patients with ch... | ||
Medical condition: Chronic proteinuric nephropathies | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004192-37 | Sponsor Protocol Number: CRO1749 | Start Date*: 2012-04-24 | |||||||||||
Sponsor Name:Joint Research Compliance Office, Imperial College | |||||||||||||
Full Title: Hellenic Anglo Research into Morning Or Night antihypertensive drug deliverY trial. | |||||||||||||
Medical condition: Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001544-26 | Sponsor Protocol Number: RASCOVID-19 | Start Date*: 2020-04-22 | ||||||||||||||||
Sponsor Name:Center for Clinical Metabolic Research, Gentofte Hospital | ||||||||||||||||||
Full Title: Effects of discontinuing renin-angiotensin system inhibitors in patients with and without COVID-19 | ||||||||||||||||||
Medical condition: Coronavirus disease 2019 (COVID-19) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002262-12 | Sponsor Protocol Number: DAPA-OB | Start Date*: 2021-05-17 |
Sponsor Name:Hospital Universitari Germans Trias i Pujol | ||
Full Title: "Effect of dapagliflozin on glomerular hyperfiltration in nondiabetic obese patients with or without treatment with ACEIs". Pilot clinical trial of efficacy, low level of intervention, unicentric, ... | ||
Medical condition: This study aims to demonstrate the hypothesis that treatment with dapagliflozin 10mg lowers in at least 10-20% of measured glomerular filtration rate (mGFR) in non-diabetic obese patients with glom... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004042-42 | Sponsor Protocol Number: DEER | Start Date*: 2014-06-19 | ||||||||||||||||
Sponsor Name:King’s College London [...] | ||||||||||||||||||
Full Title: A study to investigate the potential renoprotective role of sodium-glucose transporter-2 (SGLT-2) antagonist Dapagliflozin in Type 2 diabetic patients with diabetic nephropathy | ||||||||||||||||||
Medical condition: Diabetic Nephropathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002396-18 | Sponsor Protocol Number: 2015-602295-02 | Start Date*: 2015-11-30 | |||||||||||
Sponsor Name:Ethicare GmbH | |||||||||||||
Full Title: ORODISPERSIBLE MINITABLETS OF ENALAPRIL IN YOUNG CHILDREN WITH HEART FAILURE DUE TO CONGENITAL HEART DISEASE | |||||||||||||
Medical condition: Heart Failure due to Congenital Heart Disease | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GB (Prematurely Ended) NL (Ongoing) AT (Completed) DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004152-10 | Sponsor Protocol Number: EMPATHY | Start Date*: 2020-01-30 | ||||||||||||||||
Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI | ||||||||||||||||||
Full Title: Evaluating the Short-Term Renal and Systemic Effects of SGLT2 Inhibition in Non-Diabetic Patients at Risk of Accelerated GFR Decline Because of Glomerular Hyperfiltration: a sequential OFF-ON-OFF S... | ||||||||||||||||||
Medical condition: Obesity Renal chronic disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-017336-40 | Sponsor Protocol Number: 1235.33 | Start Date*: 2010-04-26 | |||||||||||||||||||||
Sponsor Name:Boehringer Ingelheim BV | |||||||||||||||||||||||
Full Title: Prospective, open label TElmisartan/AMlodipine single pill STudy to Assess the efficacy in patients with essential hypertension who are not controlled on RAASi mono-therapy being switched. | |||||||||||||||||||||||
Medical condition: Hypertension | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) IT (Completed) DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002785-31 | Sponsor Protocol Number: RLY5016-206p | Start Date*: 2017-08-03 | |||||||||||
Sponsor Name:Vifor Pharma, Inc. | |||||||||||||
Full Title: A Phase 2, Open-Label, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer for Oral Suspension in Children and Adolescents 2 to < 18 Years of Age with... | |||||||||||||
Medical condition: Chronic Kidney Disease and Hyperkalemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BG (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006579-41 | Sponsor Protocol Number: ANG3070-CKD-201 | Start Date*: 2022-03-07 | |||||||||||
Sponsor Name:Angion Biomedica Corp. | |||||||||||||
Full Title: A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of Safety and Efficacy Of ANG-3070 in Patients with Primary Glomerular Disease and Persistent Proteinuria | |||||||||||||
Medical condition: Primary glomerular disease and persistent proteinuria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) ES (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002299-28 | Sponsor Protocol Number: 20110203 | Start Date*: 2017-01-17 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Redu... | |||||||||||||
Medical condition: Chronic Heart Failure With Reduced Ejection Fraction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) BE (Completed) SE (Completed) CZ (Completed) ES (Completed) HU (Completed) NL (Completed) GB (Completed) PT (Completed) PL (Completed) AT (Completed) SK (Completed) BG (Completed) LT (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002636-25 | Sponsor Protocol Number: RG_13-013NS | Start Date*: 2013-09-11 |
Sponsor Name:University of Birmingham | ||
Full Title: A Randomised Multicentre Open Label Blinded End Point Trial to Compare the Effects of Spironolactone to Chlortalidone on Left Ventricular Mass and Arterial Stiffness in Stage 3 Chronic Kidney Disease | ||
Medical condition: The condition under investigation is the disease changes that occur in patients with mild kidney disease that cause them to have a high rate of diseases such as heart failure, rhythm disturbance an... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-000947-88 | Sponsor Protocol Number: 09A502 | Start Date*: 2008-02-18 | |||||||||||
Sponsor Name:ISTITUTO AUXOLOGICO ITALIANO | |||||||||||||
Full Title: Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects with Metabolic Syndrome and High-Normal Blood Pressure. | |||||||||||||
Medical condition: Hypertension, diabetes mellitus. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000225-30 | Sponsor Protocol Number: DMA-Clin-199-2013-001 | Start Date*: 2013-04-12 | |||||||||||
Sponsor Name:DiaMedica USA Inc. | |||||||||||||
Full Title: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, SINGLE DOSE AND MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PROOF OF CONCEPT OF DM-199 IN HEALTHY SUBJECTS... | |||||||||||||
Medical condition: Diabetes Mellitus type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001363-31 | Sponsor Protocol Number: M05-741 | Start Date*: 2007-05-28 | |||||||||||
Sponsor Name:Abbott GmbH & Co KG | |||||||||||||
Full Title: Estudio VITAL- Estudio del activador del receptor de la vitamina D selectivo (Paricalcitol) para la reducción de la albúmina: Estudio multicéntrico de fase II, prospectivo aleatorizado, a doble cie... | |||||||||||||
Medical condition: Nefropatía diabética Tipo 2. Type 2 diabetic nephropathy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) PT (Completed) GR (Completed) IT (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004174-64 | Sponsor Protocol Number: DMX-200-301 | Start Date*: 2022-03-08 | ||||||||||||||||
Sponsor Name:Dimerix Bioscience Pty Ltd | ||||||||||||||||||
Full Title: A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving... | ||||||||||||||||||
Medical condition: Focal segmental glomerulosclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
